When a patient has advanced gastric cancer that has spread to the brain, treatment options can be very limited. A recent case report looks at a 52-year-old man with this specific, difficult diagnosis. He received a combination of stereotactic radiosurgery (a precise form of radiation) followed by a specific drug combination called RC48 and camrelizumab.
During the follow-up period, the patient showed a partial response and eventually achieved a complete response. Most importantly, he remained disease-free for over three years after stopping his treatment. This suggests that the combination of radiation and these specific drugs might help create a lasting immune response in some patients.
It is important to note that this finding comes from a single patient case. While the results are encouraging, the evidence is currently limited because it was not a large-scale clinical trial. The patient did experience a side effect called grade 2 pneumonitis, which led to the discontinuation of his treatment. Talk to your doctor to see if these types of targeted therapies are right for your specific situation.
